Intravenous ethanol was traditionally used as a competitive inhibitor of alcohol dehydrogenase; it is effective because this enzyme has greater affinity for ethanol than for ethylene glycol or methanol. However, fomepizole has been found to be a superior therapy to ethanol, is easier to administer, and has fewer side effects. Although ethanol is a reasonable second-line therapy, there is no benefit to coadministration of fomepizole and ethanol.
If you want to change selection, open document below and click on "Move attachment"
pdf
owner:
ELBOMBARDO - (no access) - MKSAP_17.pdf, p3579
Summary
| status | not read | | reprioritisations | |
|---|
| last reprioritisation on | | | suggested re-reading day | |
|---|
| started reading on | | | finished reading on | |
|---|
Details